Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2025年5月31日
	新闻
	Molecular Assay May Help Identify People With Non-Small Cell Lung Cancer Who Could ... ASCO A 14-gene molecular assay used with patients with stage IA-IIA non-squamous non-small cell lung cancer identified those who could benefit from ... 标记为不相关
	ASCO 2025: Impact of Wildfire-Related Pollution on Survival in NSCLC The ASCO Post Inhaling wildfire-related air pollution may reduce the likelihood of survival among patients with non–small cell lung cancer (NSCLC), according to ... 标记为不相关
	T-DXd Earns Second-Line SOC for HER2+ Gastric/GEJ Cancer - Oncology Nursing News Oncology Nursing News It was also noted that interstitial lung disease/pneumonitis occurred in 13.9% of patients who received T-DXd and 1.3% who received ramucirumab plus ... 标记为不相关
	Combination therapy lowers risk of tumor progression in form of breast cancer - STAT News STAT News Summit shows mixed results from key study of lung cancer drug. The study enrolled 443 patients with previously untreated, metastatic, triple ... 标记为不相关
	Assay Can Guide Who Gets Chemo for Early-Stage NSCLC | Cancer Discovery News AACR Journals A 14-gene molecular assay can help identify patients with lung cancer could benefit from chemotherapy after surgery, according to results of a ... 标记为不相关
	Triplet therapy significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer News-Medical.net Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung ... 标记为不相关
	18.6 Million Cancer Survivors in the United States as of Jan. 1, 2025 Diabetes In Control Racial differences in treatment common, including lower likelihood of surgery for stage I to II lung cancer in Black patients. 标记为不相关
	FDA grants priority review for sevabertinib in HER2-mutant NSCLC - The Cancer Letter The Cancer Letter Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC Davis Comprehensive Cancer ... 标记为不相关
	ASCO 2025: FGFR3 Alteration Status and Outcomes with Immune Checkpoint Inhibitors in ... UroToday ... lung cancer. As such, Dr. Gupta and colleagues sought to explore the effect of FGFR3 alterations alone and with tumor mutational burden on ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈